Patent ID: 11874283
Assignee: MOREHOUSE SCHOOL OF MEDICINE
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  C  G

Claim 0:
1. A method of treating IgA nephropathy directly linked to increased levels of ET-1 compared to ET-1 levels in those without IgA nephropathy, in a mammalian subject in need thereof and diagnosed at a qualified medical center as having said IgA nephropathy, by administering an effective amount of a pharmaceutical composition comprising:
(1) an active ingredient consisting of an ET-1 antagonist; and
(2) a pharmaceutically acceptable carrier,
wherein the active ingredient is the only active ingredient in the pharmaceutical composition, wherein the subject has an increased level of ET-1 compared to a control subject, and wherein the ET-1 antagonist is selected from the group consisting of sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan and tezosentan.